"Valproic Acid" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A fatty acid with anticonvulsant properties used in the treatment of epilepsy. The mechanisms of its therapeutic actions are not well understood. It may act by increasing GAMMA-AMINOBUTYRIC ACID levels in the brain or by altering the properties of voltage dependent sodium channels.
| Descriptor ID |
D014635
|
| MeSH Number(s) |
D02.241.081.944.509.900 D10.251.400.895.593.900
|
| Concept/Terms |
Valproic Acid- Valproic Acid
- Propylisopropylacetic Acid
- 2-Propylpentanoic Acid
- 2 Propylpentanoic Acid
- Divalproex
Divalproex Sodium- Divalproex Sodium
- Semisodium Valproate
- Valproic Acid, Sodium Salt (2:1)
|
Below are MeSH descriptors whose meaning is more general than "Valproic Acid".
Below are MeSH descriptors whose meaning is more specific than "Valproic Acid".
This graph shows the total number of publications written about "Valproic Acid" by people in this website by year, and whether "Valproic Acid" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2004 | 1 | 0 | 1 |
| 2014 | 1 | 0 | 1 |
| 2016 | 0 | 1 | 1 |
| 2017 | 10 | 6 | 16 |
| 2018 | 10 | 3 | 13 |
| 2019 | 1 | 1 | 2 |
| 2020 | 0 | 1 | 1 |
To return to the timeline, click here.
Below are the most recent publications written about "Valproic Acid" by people in Profiles.
-
SAVER: sodium valproate for the epigenetic reprogramming of high-risk oral epithelial dysplasia-a phase II randomised control trial study protocol. Trials. 2021 Jul 05; 22(1):428.
-
The COVID-19 conundrum: Where both the virus and treatment contribute to delirium. Geriatr Nurs. 2021 Jul-Aug; 42(4):955-958.
-
Potential repurposing of the HDAC inhibitor valproic acid for patients with COVID-19. Eur J Pharmacol. 2021 May 05; 898:173988.
-
Opsoclonus-Myoclonus-Ataxia Syndrome (OMAS) Associated with SARS-CoV-2 Infection: Post-Infectious Neurological Complication with Benign Prognosis. Tremor Other Hyperkinet Mov (N Y). 2021 02 10; 11:7.
-
Opsoclonus-myoclonus syndrome, a post-infectious neurologic complication of COVID-19: case series and review of literature. J Neurovirol. 2021 02; 27(1):26-34.
-
Diagnosing and managing childhood absence epilepsy by telemedicine. Epilepsy Behav. 2021 02; 115:107404.
-
The Pharmaceutical Year That Was, 2020. Pharmaceut Med. 2020 12; 34(6):365-368.
-
[Recommendations about the Use of Psychotropic Medications during the COVID-19 Pandemic]. Acta Med Port. 2020 Oct 01; 33(10):693-702.
-
Interferon-Induced Transmembrane Protein (IFITM3) Is Upregulated Explicitly in SARS-CoV-2 Infected Lung Epithelial Cells. Front Immunol. 2020; 11:1372.
-
Immunopharmacological management of COVID-19: Potential therapeutic role of valproic acid. Med Hypotheses. 2020 10; 143:109891.